Sangary Kathirgamakarthigeyan

197 Moving to a daily treatment regime for 8 fraction Lung SABR treatments

Catherine G.N. Sharma, A. Pascoe, Sangary Kathirgamakarthigeyan, Ananth Sivanandan et autres

gb (code pays fourni par la source)

THE LANDSCAPE OF SECOND LINE (AND BEYOND) TREATMENTS FOR GLIOBLASTOMA (IDH WILDTYPE) IN THE UK IN 2021: AN UPDATE FROM THE HISTO-MOL GBM COLLABORATIVE

Stephen David Robinson, Sean Farrell, Attika Chaudhary, Simon Lammy et autres

Abstract AIMS First line treatment for glioblastoma has been standardised for the last 20 years. However, there is signifi- cant variation in choice of second (and subsequent) line treatments. In particular the role of re-resection and re-irradiation are unclear. Using a large …

gb, jp (code pays fourni par la source)

158 Who gets acute oesophagitis with radical radiotherapy for locally-advanced non-small cell lung cancer (NSCLC)?

Sangary Kathirgamakarthigeyan, Catherine G.N. Sharma, Laura Miller, Ashleigh Butcher et autres

gb (code pays fourni par la source)

Thymic epithelial tumour radiotherapy in the UK: A survey of current clinical practice

Stephen David Robinson, Abigail Gault, Sangary Kathirgamakarthigeyan, DAVID M. GILLIGAN

Significant variation in treatment centre setup and radiotherapy practice for thymic epithelial tumours (TET) was identified through a comprehensive survey of current UK Clinical (Radiation) Oncology practice. Multi-centre collaboration and wider TET specific multidisciplinary team meetings are needed and will be essential …

gb (code pays fourni par la source)

Radical treatment for patients with brain only oligometastatic non-small cell lung cancer- long term survival is possible

A. Pascoe, Emily Lynne Robertson, Sangary Kathirgamakarthigeyan, Micheál O’Cathail

Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19

Csilla Várnai, Claire Palles, Roland R. Arnold, Helen M. Curley et autres

Importance: Large cohorts of patients with active cancers and COVID-19 infection are needed to provide evidence of the association of recent cancer treatment and cancer type with COVID-19 mortality. Objective: To evaluate whether systemic anticancer treatments (SACTs), tumor subtypes, patient demographic characteristics …

gb (code pays fourni par la source)

Routine imaging following lung SABR infrequently changes patient management

Sarah H. Taylor, Sangary Kathirgamakarthigeyan, A. Pascoe

How has the coronavirus pandemic impacted chemoradiotherapy for stage 3 non-small cell lung cancer (NSCLC) in our centre?

Sangary Kathirgamakarthigeyan, Karen Foweraker, Kerstie Johnson, Ananth Sivanandan et autres

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey, Sarah Briggs et autres

gb (code pays fourni par la source)